Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study.
Karuna ChavalertsakulYuda SutherasanTananchai PetnakKanin ThammavaranucuptSuppachok KirdlarpViboon BoonsarngsukSomnuek SungkanuparphPublished in: International journal of general medicine (2024)
In patients with moderate to severe COVID-19 pneumonia, Remdesivir did not demonstrate superior benefits over Favipiravir regarding 29-day mortality, 15-day recovery rates, or hospital and ICU stay lengths. However, further investigation into the 15-day cumulative survival rate revealed a trend towards improved survival in the Remdesivir group.
Keyphrases
- coronavirus disease
- sars cov
- high intensity
- early onset
- intensive care unit
- free survival
- healthcare
- cardiovascular events
- single cell
- respiratory syndrome coronavirus
- community acquired pneumonia
- drug induced
- mechanical ventilation
- emergency department
- coronary artery disease
- acute care
- type diabetes
- extracorporeal membrane oxygenation
- electronic health record